Patients clinical and biological characteristics
| . | Overall . | Altered . | WT . | . |
|---|---|---|---|---|
| N = 218 . | N = 56 . | N = 162 . | P . | |
| Patient metrics | ||||
| Median age, y (range) | 30.6 (16.3-59.1) | 30.6 (17.6-58.1) | 30.8 (16.3-59.1) | .44 |
| Sex ratio (M/F) | 155/63 | 36/20 | 119/43 | .23 |
| Disease progression | ||||
| Median WBC, G/L (range) | 35.1 (0.9-645) | 32.4 (0.9-456) | 36.7 (2.8-645) | .17 |
| CNS infiltration | 24/218 (11%) | 5/56 (9%) | 19/162 (12%) | .81 |
| Treatment response | ||||
| Good prednisone response | 117/218 (54%) | 22/56 (39%) | 95/162 (59%) | .01 |
| Good bone marrow response | 119/215 (55%) | 15/56 (26%) | 104/159 (65%) | <0.001 |
| Complete remission | 201/218 (92%) | 54/56 (96%) | 147/162 (91%) | .25 |
| Postinduction MRD >10-3 | 30/122 (25%) | 19/34 (56%) | 11/88 (13%) | <.001 |
| HSCT among CR | 78/201 (39%) | 30/54 (56%) | 48/147 (33%) | .005 |
| Clinical outcomes | ||||
| 5-y CIR, % (95% CI) | 33% (27-40) | 37% (26-52) | 31% (24-39) | .34 |
| Hazard ratio (95% CI) | 0.84 (0.49-1.46) | 1.18 (0.68 to 2.05) | .55 | |
| 5-y OS, % (95% CI) | 65% (59-71) | 62% (48-74) | 67% (59-73) | .62 |
| . | Overall . | Altered . | WT . | . |
|---|---|---|---|---|
| N = 218 . | N = 56 . | N = 162 . | P . | |
| Patient metrics | ||||
| Median age, y (range) | 30.6 (16.3-59.1) | 30.6 (17.6-58.1) | 30.8 (16.3-59.1) | .44 |
| Sex ratio (M/F) | 155/63 | 36/20 | 119/43 | .23 |
| Disease progression | ||||
| Median WBC, G/L (range) | 35.1 (0.9-645) | 32.4 (0.9-456) | 36.7 (2.8-645) | .17 |
| CNS infiltration | 24/218 (11%) | 5/56 (9%) | 19/162 (12%) | .81 |
| Treatment response | ||||
| Good prednisone response | 117/218 (54%) | 22/56 (39%) | 95/162 (59%) | .01 |
| Good bone marrow response | 119/215 (55%) | 15/56 (26%) | 104/159 (65%) | <0.001 |
| Complete remission | 201/218 (92%) | 54/56 (96%) | 147/162 (91%) | .25 |
| Postinduction MRD >10-3 | 30/122 (25%) | 19/34 (56%) | 11/88 (13%) | <.001 |
| HSCT among CR | 78/201 (39%) | 30/54 (56%) | 48/147 (33%) | .005 |
| Clinical outcomes | ||||
| 5-y CIR, % (95% CI) | 33% (27-40) | 37% (26-52) | 31% (24-39) | .34 |
| Hazard ratio (95% CI) | 0.84 (0.49-1.46) | 1.18 (0.68 to 2.05) | .55 | |
| 5-y OS, % (95% CI) | 65% (59-71) | 62% (48-74) | 67% (59-73) | .62 |
CI, confidence interval; CNS, central nervous system; CR, complete response; F, female; HSCT, hematopoietic stem cell transplant; M, male; WBC, white blood cell.